吉非替尼片致心肌炎1例分析

doi:10.19803/j.1672-8629.20250143

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (9): 1053-1055.
DOI: 10.19803/j.1672-8629.20250143

吉非替尼片致心肌炎1例分析

吴倩, 覃勇^*, 望庐山, 韩忠宇

三峡大学第一临床医学院康复医学科,湖北宜昌 443000

收稿日期:2025-03-07 出版日期:2026-09-15 发布日期:2026-09-15
通讯作者: ^*覃勇,男,本科,主任医师·硕导,临床医学。E-mail: 13032714025@163.com
作者简介:吴倩,女,硕士,主治医师,临床医学。
基金资助:
湖北省自然科学基金资助项目（2023AFB689）

One case of myocarditis caused by gefitinib tablets

Wu Qian, Qin Yong^*, Wang Lushan, Han Zhongyu

Department of Rehabilitation Medicine, the First College of Clinical Medical Science, China Three Gorges University, Yichang Hubei 443000, China

Received:2025-03-07 Online:2026-09-15 Published:2026-09-15

摘要/Abstract

摘要： 目的分析吉非替尼引起的心肌炎不良反应,为临床安全用药提供参考。方法梳理1例吉非替尼片致心肌炎患者的诊治经过,结合文献分析,探讨吉非替尼致心肌炎的机制及处理措施。结果患者口服吉非替尼3月余后出现胸闷、呼吸困难伴咯血症状,考虑吉非替尼片所致心肌炎,立即停用吉非替尼,予补液、利尿、营养心肌等对症治疗后症状好转。结论使用吉非替尼时需警惕心肌炎等不良反应的发生,加强监测,早期识别并及时干预。

关键词: 吉非替尼, 非小细胞肺癌, 心肌炎, 药品不良反应

Abstract: Objective To find out about myocarditis induced by gefitinib in order provide a reference for clinical safe medication. Methods The diagnostic and therapeutic process of a patient with myocarditis induced by gefitinib was reviewed. Related literature was retrieved to explore the mechanism of and management strategies for gefitinib-induced myocarditis. Results After more than three months of treatment with gefitinib, the patient developed chest tightness, dyspnea, and hemoptysis. Gefitinib-induced myocarditis was suspected. The drug was immediately withdrawn before symptomatic treatments including fluid resuscitation, diuresis, and myocardial nutritional support were offered. The patient's symptoms subsequently improved. Conclusion Adverse reactions such as myocarditis should be monitored during the use of gefitinib. Enhanced surveillance, early identification, and prompt interventions are required.

Key words: Gefitinib, Non-Small Cell Lung Cancer, Myocarditis, Adverse Drug Reactions

中图分类号:

吴倩, 覃勇, 望庐山, 韩忠宇. 吉非替尼片致心肌炎1例分析[J]. 中国药物警戒, 2026, 23(9): 1053-1055.

Wu Qian, Qin Yong, Wang Lushan, Han Zhongyu. One case of myocarditis caused by gefitinib tablets[J]. Chinese Journal of Pharmacovigilance, 2026, 23(9): 1053-1055.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250143

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I9/1053

参考文献

[1] Liu Z B, Kim M O.From gefitinib to amivantamab: progress and perspe-ctives of therapies targeting the epidermal growth factor receptor in the era of precision oncology[J]. J Cancer Prev, 2026, 31: 11-19.
[2] Ricci J C, Farahani N A, Davis C J, et al.A comparative review of myocarditis in pediatrics versus adults:pathogenesis, diagnosis, and management[J]. Front Immunol, 2025, 16: 1601307.
[3] Cadour T, Dos J F P, Catania R, et al. Cardiac imaging findings at nongated chest CT in the emergency department[J]. Radiographics, 2025, 45: e250001.
[4] An Pengjiao, Yang Liping.Retrospective review of 416 adverse drug reaction cases of gefitinib[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(7): 716-723.
[5] Yu Yanhua.One case of sensorineural hearing loss induced by gefitinib[J]. Herald of Medicine(医药导报), 2019, 38(8): 1098-1099.
[6] Liao Yufang, Zou Ze, Yue Jiannong.Medication review of a rare case of gefitinib-induced liver injury with cholecystitis in a patient with lung adenocarcinoma by clinical pharmacists[J]. China Pharmacy(中国药房), 2020, 31(20): 2546-2550.
[7] Deng Huijie, Liang Li, Chen Yan, et al.Cardiac and fatal adverse events of epidermal growth factor receptor inhibitors based on the FAERS database[J]. Chinese Journal of New Drugs(中国新药杂志), 2023, 32(8): 858-864.
[8] Truell J S, Fishbein M C, Figlin R.Myocarditis temporally related to the use of gefitinib (iressa)[J]. Arch Pathol Lab Med, 2005, 129: 1044-1046.
[9] Pan Xiaoping, Cai Guangxian, Liu Boyan, et al.Erlotinib-induced sick sinus syndrome[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2009, 11(4): 276-277.
[10] Liu Qing.One case of sypertension and myocardial ischemia induced by erlotinib in an elderly patient with lung cancer[J]. Chinese Journal of Health Care and Medicine(中华保健医学杂志), 2015, 17(5): 427-428.
[11] Kong Yingli, Xin Xinyuan, Shi Huihui, et al.Osimertinib mesylate tablets-induced heart failure: a case report[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2025, 22(11): 1300-1303.
[12] Lou Anqi, Zhen Jiancun.Risk of osimertinib-induced cardiotoxicity based on the FAERS database[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2022, 25(9): 788-792.
[13] Naranjo C A, Busto U, Sellers E M, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[14] Li X, Lin Y P, Lin S, et al.Advancements in understanding cardiotoxicity of EGFR-TKIs in non-small cell lung cancer treatment and beyond[J]. Front Pharmacol, 2024, 15: 1404692.
[15] Gulinigaer Maimaitituersun.Gefitinib-induced cardiotoxicity in patients with non-small cell lung cancer[D]. Urumqi: Xinjiang Medical University, 2023.
[16] Zhang J, Qi S S, Du Y Y, et al.Effect of quercetin on inhibiting gefitinib-activated non-small cell lung cancer-induced cell pyroptosis in cardiomyocytes via modulating mitochondrial autophagy mediated by the SHP2/ROS/AMPK/XBP-1/DJ-1 signaling pathway[J]. Oncol Rep, 2025, 53(5): 57.

吉非替尼片致心肌炎1例分析

One case of myocarditis caused by gefitinib tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	冯思琪, 倪雨晨, 胡冯译, 刘玥, 叶小飞, 郭晓晶. 细胞治疗产品上市后长期安全性监测的国际经验与中国优化路径[J]. 中国药物警戒, 2026, 23(9): 975-981.
[2]	刘红亮, 宋海波, 米岚, 孟康康, 王涛, 漆燕, 贾晋生. 基于大语言模型应用的个例安全性报告数据清洗方法探讨[J]. 中国药物警戒, 2026, 23(9): 1017-1022.
[3]	赵志伟, 柯文缘, 杨雪, 陈晓博, 夏旭东. 1358例碘克沙醇注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(9): 1040-1044.
[4]	潘恩, 崔小康, 徐滨, 荣右明, 范晓, 马晓东, 李霞. 1115例草酸艾司西酞普兰片不良反应报告分析[J]. 中国药物警戒, 2026, 23(9): 1045-1049.
[5]	尚家海, 龙娇娇, 刘雅瑞, 卢圆圆. 注射用尖吻蝮蛇血凝酶致儿童结膜充血2例分析[J]. 中国药物警戒, 2026, 23(9): 1050-1052.
[6]	孙玲玲, 方薇, 王雨廷, 李进峰, 杨依磊. 阿昔洛韦咀嚼片致急性重度肝损伤1例分析[J]. 中国药物警戒, 2026, 23(9): 1056-1058.
[7]	王昆, 徐磊, 汪岑, 侯文平, 刘俊保, 苏长海. 地高辛片致舞蹈症1例分析[J]. 中国药物警戒, 2026, 23(9): 1059-1061.
[8]	邢璐宇, 邢迎红, 范文, 张淑翼. 注射用哌拉西林钠他唑巴坦钠致横纹肌溶解1例分析[J]. 中国药物警戒, 2026, 23(9): 1062-1064.
[9]	向群, 傅大莉. 药源性认知障碍的致病药物及疾病风险评估研究进展[J]. 中国药物警戒, 2026, 23(9): 1075-1080.
[10]	吕欣鸽, 刘艾嘉, 武一, 潘晨, 王雨婷, 崔向丽. 免疫检查点抑制剂相关甲状腺功能障碍的多中心病例分析[J]. 中国药物警戒, 2026, 23(8): 892-897.
[11]	李剑屏, 杜宁, 唐敏, 周子原, 左靖. 691例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 904-908.
[12]	白丽琴, 聂红科, 杨淑婷, 蒋晓峰. 214例肌苷注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 909-913.
[13]	张育茂, 刘君波, 罗千江, 谭槟滢, 邓彬, 邢惟青, 李玉珍. 口服复方聚乙二醇电解质散（Ⅱ）肠道准备致呕血2例分析[J]. 中国药物警戒, 2026, 23(8): 931-933.
[14]	高朝政, 赵一帆, 苏丽, 李平. 注射用芦康沙妥珠单抗致癌症患者急性疼痛2例分析[J]. 中国药物警戒, 2026, 23(8): 934-937.
[15]	谢华丽, 关碧茜, 卓羽波, 何洁丽, 陈喆. 注射用芦康沙妥珠单抗致序贯性超敏反应1例分析[J]. 中国药物警戒, 2026, 23(8): 938-940.